Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Age-adjusted high-dose chemotherapy and autologous stem cell transplant in elderly and fit primary CNS lymphoma patients
DRKS00011932Phase 2Completed
- Sponsor
- Universitätsklinikum Freiburg
- Start
- Aug 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab, methotrexate, cytarabine, busulfan and thiotepa in primary central nervous system lymphoma (PCNSL) and mature B-cell lymphoma, sponsored by Universitätsklinikum Freiburg. Started Aug 2017; status: completed.
02
Drugs
rituximabmethotrexatecytarabinebusulfanthiotepa
03
Conditions
primary central nervous system lymphoma (PCNSL)mature B-cell lymphoma
Beyond the preview
Go deeper on DRKS00011932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00011932.